CoChat

Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH‐SY 5Y cells

Open access
Jalewa, Jaishree, Sharma, Mohit Kumar, Hölscher, Christian · 2016 · Journal of Neurochemistry
Cited by 73

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Currently, there is no viable treatment available for Parkinson's disease (PD) that stops or reverses disease progression. Interestingly, studies testing the glucagon‐like‐peptide‐1 (GLP‐1) mimetic Exendin‐4 have shown neuroprotective/neurorestorative properties in pre‐clinical tests and in a pilot clinical study of PD. Incretin analogues were originally developed to treat type 2 diabetes and several are currently on the market. In this study, we tested novel incretin analogues on the dopaminergic SH‐SY 5Y neuroblastoma cells against a toxic mitochondrial complex I inhibitor, Rotenone. Here, we investigate for the first time the effects of six different incretin receptor agonists – Liraglutide, D‐Ser2‐Oxyntomodulin, a GLP‐1/GIP Dual receptor agonist,dA la(2)‐GIP‐GluPal, Val(8)GLP‐1‐GluPal and exendin‐4. Post‐treatment with doses of 1, 10 or 100 nM of incretin analogues for 12 h increased the survival of SH‐SY 5Y cells treated with 1 μM Rotenone for 12 h. Furthermore, we studied the post‐treatment effect of 100 nM incretin analogues against 1 μM Rotenone stress on apoptosis, mitochondrial stress and autophagy markers. We found significant protective effects of the analogues against Rotenone stress on cell survival and on mitochondrial and autophagy‐associated markers. The novel GLP‐1/GIP Dual receptor agonist was superior and effective at a tenfold lower concentration compared to the other analogues. Using the Phosphatidylinositol 3‐kinase (PI 3K) inhibitor,LY 294002, we further show that the neuroprotective effects are partially PI 3K‐independent. Our data suggest that the neuroprotective properties exhibited by incretin analogues against Rotenone stress involve enhanced autophagy, increased Akt‐mediated cell survival and amelioration of mitochondrial dysfunction. These mechanisms can explain the neuroprotective effects of incretin analogues reported in clinical trials. imageGLP‐1,GIP and dual incretin receptor agonists showed protective effects in SH‐SY 5Y cells treated with the stressor Rotenone. The novel GLP‐1/GIP dual receptor agonist was superior and effective at a tenfold lower concentration compared to the other analogues. The drugs protected the cells from rotenone‐induced impairment in cell growth and Akt activation, mitochondrial damage, impairments of autophagy and apoptotic cell signalling. See paper for details.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jnc.13736

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 73

Metadata

Authors
Jalewa, J., Sharma, M. K., & Hölscher, C.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2016-08-24
Volume
139
Issue
1
Pages
55-67
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W2468864843
Cited by
73
References
20
FWCI
7.51
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH‐SY 5Y cells. https://app.cochat.ai/papers/10.1111/jnc.13736
The paper
Jalewa, J., Sharma, M. K., & Hölscher, C. (2016). Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH‐SY 5Y cells. Journal of Neurochemistry. https://doi.org/10.1111/jnc.13736

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.